[1] SZNOL M, POSTOW M A, DAVIES M J, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management[J]. Cancer Treat Rev, 2017, 58:70-76.
[2] 殷海涛, 张皓, 李晓林. 老年肿瘤患者的特点与药物治疗新趋势[J].实用老年医学,2013,27(1):8-11.
[3] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3):230-241.
[4] KITAJIMA K, ASHIDA K, WADA N, et al. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab[J]. Jpn J Clin Oncol, 2017,47(5):463-466.
[5] 李佳蓉, 关海霞. 内分泌学与肿瘤学医师须知:免疫检查点抑制剂致内分泌腺体损伤[J].中华内分泌代谢杂志, 2019, 35(7):548-553.
[6] BYUN D J, WOLCHOK J D, ROSENBERG L M, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017,13(4):195-207.
[7] BARROSO-SOUSA R, OTT P A, HODI F S, et al. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management[J]. Cancer, 2018, 124(6):1111-1121.
[8] FAJE A, REYNOLDS K, ZUBIRI L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis[J]. Eur J Endocrinol, 2019, 181(3):211-219.
[9] JBAG H, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(4):264-266.
[10]段炼, 王林杰, 斯晓燕, 等. 免疫检查点抑制剂相关内分泌不良反应的临床诊治建议[J].中国肺癌杂志, 2019, 22(10):649-652.
[11]LUPI I, BRANCATELLA A, COSOTTINI M, et al. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases[J]. Endocrinol Diabetes Metab Case Rep, 2019. DOI: 10.1530/EDM-19-0102.
[12]ELIA G, FERRARI S M, GALDIERO M R, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1):101370.
[13]SHIBA M, INABA H, ARIYASU H, et al. Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody[J]. Intern Med, 2018, 57(14):2029-2034. |
